Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Phase 3 Recruiting
264 enrolled
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Phase 3 Recruiting
231 enrolled
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 Recruiting
52 enrolled
ETNA
Phase 2 Recruiting
30 enrolled
MG-ARCADIA
Recruiting
50 enrolled
Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy
Recruiting
75 enrolled
roMyG
Phase 2/3 Recruiting
12 enrolled
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Recruiting
450 enrolled
ziMyG
Phase 2/3 Recruiting
8 enrolled
SYNAPSE-MG
Phase 2 Recruiting
84 enrolled
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
Phase NA Recruiting
100 enrolled
EPIC
Phase 3 Recruiting
115 enrolled
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Phase 1 Recruiting
6 enrolled
OCTAGON
Phase 4 Recruiting
75 enrolled
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3 Recruiting
120 enrolled
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 Recruiting
32 enrolled
THYME
Phase 2 Recruiting
15 enrolled
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Phase 2/3 Recruiting
66 enrolled
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1/2 Recruiting
15 enrolled
RELIEVE
Phase 3 Recruiting
180 enrolled
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 Recruiting
12 enrolled
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Phase 3 Recruiting
146 enrolled
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Phase 4 Recruiting
40 enrolled
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3 Recruiting
100 enrolled
MG-Ex
Phase NA Recruiting
20 enrolled
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Phase NA Recruiting
6 enrolled
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Phase NA Recruiting
50 enrolled
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 2/3 Recruiting
12 enrolled
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Phase NA Recruiting
12 enrolled
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Phase 3 Recruiting
180 enrolled
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Phase 3 Recruiting
199 enrolled 11 charts
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Phase 1 Recruiting
30 enrolled
Zilucoplan for Severe gMG Exacerbations
Phase 3 Recruiting
15 enrolled
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
500 enrolled
ADAPT Jr
Phase 2/3 Recruiting
12 enrolled
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Recruiting
70 enrolled
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Recruiting
680 enrolled
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Recruiting
279 enrolled
EARLY-MG
Recruiting
30 enrolled
Synergy-MG
Phase 1/2 Recruiting
96 enrolled
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Phase 1 Recruiting
120 enrolled
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Phase 2 Recruiting
70 enrolled
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Recruiting
40 enrolled
TREAT-OMG
Recruiting
200 enrolled